Trinity Biotech (TRIB) Total Debt (2009 - 2025)

Trinity Biotech has disclosed Total Debt across 15 years of filings, most recently posting $83.6 million for Q2 2025.

• Total Debt for Q2 2025 came in at $83.6 million, up 24.37% year-over-year; the trailing twelve-month figure through Jun 2025 was $83.6 million (up 24.37% YoY), and the FY2024 annual result was $74.0 million, up 82.23% from the prior year.
• Total Debt came in at $83.6 million for Q2 2025 at Trinity Biotech, up from $74.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $83.6 million in Q2 2025 to a low of $31000.0 in Q4 2021.
• The 5-year median for Total Debt is $48.4 million (2022), against an average of $53.0 million.
• Across the five-year window, Total Debt surged 147867.74% in 2022 and tumbled 34.91% in 2023, its largest moves.
• Trinity Biotech's Total Debt stood at $31000.0 in 2021, then soared by 147867.74% to $45.9 million in 2022, then decreased by 11.41% to $40.6 million in 2023, then jumped by 82.23% to $74.0 million in 2024, then grew by 12.96% to $83.6 million in 2025.
• The last three Total Debt figures came in at $83.6 million (Q2 2025), $74.0 million (Q4 2024), and $67.0 million (Q3 2024), per Business Quant data.